Risperdal gynecomastia lawsuit: the $2.2 billion DOJ settlement, the $800 million 2021 mass tort resolution, and what remains of the litigation in 2026

Risperdal (risperidone) is an atypical antipsychotic that Janssen Pharmaceuticals (a Johnson & Johnson subsidiary) marketed beginning in 1993 after FDA approval for schizophrenia in adults. In 2006, FDA approved the drug for use in children and adolescents with schizophrenia and irritability associated with autism. Between 1993 and 2006, Janssen marketed Risperdal extensively for off-label use in children, including for behavioral conditions that were not on the approved label. That off-label marketing campaign produced both criminal and civil liability, and a separate stream of personal injury cases focused on a specific adverse effect: gynecomastia.

Gynecomastia is the development of breast tissue in males. The condition is caused by elevated levels of prolactin, a hormone that promotes breast tissue growth and is normally suppressed in male physiology. Risperdal substantially elevates prolactin, and in young male patients (particularly adolescents whose endocrine systems are still developing), the prolactin elevation can produce permanent breast tissue development that, once formed, generally requires mastectomy to remove.

What was the Risperdal off-label marketing settlement?

In November 2013, the DOJ announced a $2.2 billion resolution after Janssen pleaded guilty to criminal and civil charges for promoting Risperdal off-label. The total included a $400 million criminal fine, a $1.25 billion civil settlement, and a $149 million state Medicaid settlement, covering illegal marketing to elderly dementia patients, children, and other unapproved populations.

In November 2013, the U.S. Department of Justice announced that Janssen had pleaded guilty to criminal and civil charges related to Risperdal off-label promotion. The total resolution was $2.2 billion: a $400 million criminal fine plus a $1.25 billion civil settlement plus a $149 million state Medicaid settlement, with the remainder allocated across various federal and state recovery components.

The DOJ findings were specific: Janssen had promoted Risperdal for use in elderly patients with dementia (an off-label use with a separately documented mortality risk), for use in children before FDA approval for pediatric use, and for use in patients with developmental disabilities and behavioral conditions for which the drug was not approved. The marketing campaign included payments to pharmacists, kickback arrangements with long-term care facilities, and substantial marketing investment directed at pediatricians and child psychiatrists despite the absence of FDA approval for pediatric use.

The DOJ settlement is the financial backbone of the broader Risperdal litigation context, even though it did not directly compensate individual injured patients. Janssen's admissions about its marketing practices became evidentiary foundation for the individual gynecomastia cases that followed.

What happened with the $8 billion Risperdal verdict?

In February 2015, a Pennsylvania jury issued the first major Risperdal gynecomastia verdict, awarding $2.5 million to Austin Pledger. The most notable verdict came in October 2019 when a Philadelphia jury awarded $8 billion in punitive damages to a single plaintiff. That award was later reduced on appeal to approximately $6.8 million.

The first major gynecomastia verdict was in February 2015. A Pennsylvania jury awarded $2.5 million in compensatory damages to Austin Pledger, an Alabama plaintiff who began taking Risperdal at age 8 for autism in 2002 (off-label at the time) and developed 46DD breast tissue. The jury found that Janssen failed to warn about the gynecomastia risk and that the failure caused Pledger's injury. Pennsylvania law barred punitive damages because the defendant's principal place of business was New Jersey, which prohibits punitive damages in product liability claims involving federally-approved medications. The Pennsylvania Supreme Court declined to review the verdict on appeal.

The Murray case was the first of many. The Pennsylvania Court of Common Pleas became the primary forum for Risperdal mass tort litigation, eventually consolidating more than 13,000 cases. Individual verdicts varied widely; some plaintiffs received nominal awards, others received substantial verdicts.

The most notable verdict was in October 2019, when a Philadelphia jury awarded $8 billion in punitive damages to a single plaintiff. The verdict was substantially reduced on appeal (ultimately to approximately $6.8 million), but the original award is one of the largest punitive damages verdicts in U.S. pharmaceutical litigation history. The reduction is the typical pattern; juries occasionally produce nominal-dollar-range punitive awards that courts then bring back to constitutional due-process bounds, but the deterrent effect of the original jury finding persists.

How much was the 2021 Risperdal mass settlement?

In October 2021, Janssen agreed to settle approximately 9,000 Risperdal gynecomastia cases for roughly $800 million total. The per-case average was approximately $89,000 to $95,000, depending on injury severity, age at exposure, and case-specific factors. This settlement resolved the substantial majority of pending cases and ended the active mass tort phase.

In October 2021, Janssen agreed to a confidential settlement that resolved approximately 9,000 Risperdal cases for a total of approximately $800 million. Wisner Baum (one of the firms representing plaintiffs) has separately reported the average individual settlement at approximately $95,000.

The 2021 settlement did not admit liability. Janssen continued to deny wrongdoing in the public framing of the settlement, characterizing it as a business decision to avoid continued litigation costs. The settlement resolved the substantial majority of pending Risperdal cases and effectively ended the active mass tort phase of the litigation.

What remains of the Risperdal litigation in 2026?

As of 2026, the Risperdal litigation is largely resolved. The federal MDL has wound down, the Philadelphia mass tort docket is over 98% resolved, and new filings are minimal. Minors who recently turned 18 may still have actionable claims, and Janssen continues resolving remaining cases through confidential individual settlements at predictable per-case values.

The 2026 litigation landscape is sparse. As of early 2026:

The federal MDL has effectively wound down. Most cases were transferred back to home jurisdictions or resolved through the 2021 settlement.

The Philadelphia Court of Common Pleas mass tort docket is over 98% resolved. The remaining cases are mostly individual claims with unusual procedural posture or claimants who declined to participate in the 2021 settlement.

New filings are minimal. The statute of limitations has run in most jurisdictions for adult plaintiffs; minors who developed gynecomastia and recently turned 18 (and whose limitations period now starts running) may still have actionable cases.

Janssen continues to resolve remaining claims through confidential individual settlements. The financial framework is well-established at this point; per-case values are predictable.

The 2019 $8 billion verdict appeal has fully concluded. The reduced verdict stands; no new trial risk from that line of cases.

For a person who developed gynecomastia after taking Risperdal as a child or adolescent, the current question is whether your specific case falls within an unexpired statute of limitations. The relevant clock is generally either two to four years from when you (or your guardian) knew or reasonably should have known the gynecomastia was caused by Risperdal, or in most states, from when you turned 18 if you were a minor at the time of exposure. The discovery rule and the minority tolling rule together extend the limitations period for many late-discovered cases, but the analysis is state-specific.

What legal framework did Risperdal establish for pediatric drug exposure?

The Risperdal litigation established three key principles for pediatric pharmaceutical cases: prolactin-elevating medications require specific gynecomastia warnings for adolescent males, off-label marketing to unapproved populations supports failure-to-warn claims, and pediatric injury cases carry valuation premiums over comparable adult cases due to stronger jury responses to permanent childhood injuries.

The Risperdal litigation is notable for the framework it established around pediatric exposure to psychiatric medications generally. Three principles became established through the case law:

Prolactin-elevating medications carry a specific risk profile in adolescent males that requires meaningful warning, not generic adverse-event disclosure. The 2002-2006 Risperdal label that characterized gynecomastia risk as "low" was found inadequate by multiple juries.

Off-label marketing to populations not covered by FDA approval, where adverse event profiles are different from the approved population, supports failure-to-warn claims even when the prescription was technically within the prescribing physician's discretion. Doctors prescribing off-label rely on the manufacturer's marketing representations; if those representations understate risk for the off-label population, the manufacturer is exposed.

Pediatric injury cases have valuation premiums that adult cases do not. Juries respond more strongly to permanent physical injuries in children, and verdicts in the Risperdal pediatric cases consistently ran higher than the underlying medical severity might suggest in an adult comparator.

These principles have carried into subsequent pharmaceutical litigation, including the more recent Elmiron vision loss cases (also a Janssen product, similar failure-to-warn theory).

How does Risperdal compare to other mass torts?

The Risperdal litigation shares structural features with several related pharmaceutical mass torts, including the Tylenol autism MDL, Singulair suicidal ideation cases, Suboxone tooth decay litigation, and Elmiron vision loss cases. Each involves delayed or inadequate warnings, chronic exposure, and irreversible injury, though the specific science and current litigation posture differ.

The framework shares features with several Halstonberg-covered litigations:

Practical takeaway

For individuals who took Risperdal as children or adolescents and developed gynecomastia, the statute of limitations analysis is the critical first step. Most states apply a discovery rule and minority tolling, meaning the limitations clock may start at age 18 or when the causal link to Risperdal was reasonably discoverable.

If you took Risperdal as a child or adolescent and developed gynecomastia, the limitations period analysis is the critical first step.

If you took Risperdal as an adult and developed gynecomastia, your case is on a different timeline. Adult-onset gynecomastia is documented in the literature but the cases are individually weaker than pediatric cases (lower prolactin sensitivity in adult endocrine systems, more confounding factors), and the statute of limitations has run in most jurisdictions for adult cases first prescribed in the 2000s.

If you are the parent of a child who is currently taking Risperdal or has been prescribed it recently, the medical conversation with the prescribing physician is the priority. The drug has legitimate uses, and the warning is now in place; what changed after 2006 was the labeling, not the underlying medical considerations. Pediatric endocrine monitoring during treatment is the standard-of-care response to known prolactin elevation.

The litigation that produced the warning is mostly closed. The medical framework it produced is the more durable contribution.